IN2015DN03229A - - Google Patents

Info

Publication number
IN2015DN03229A
IN2015DN03229A IN3229DEN2015A IN2015DN03229A IN 2015DN03229 A IN2015DN03229 A IN 2015DN03229A IN 3229DEN2015 A IN3229DEN2015 A IN 3229DEN2015A IN 2015DN03229 A IN2015DN03229 A IN 2015DN03229A
Authority
IN
India
Prior art keywords
specific binding
conjugated
ibd
molecule
binding member
Prior art date
Application number
Other languages
English (en)
Inventor
Giovanni Neri
Kathrin Schwager
Melanie Ruzek
Denise Ohara
Jianqing Chen
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN03229(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Philogen Spa filed Critical Philogen Spa
Publication of IN2015DN03229A publication Critical patent/IN2015DN03229A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN3229DEN2015 2012-10-03 2012-10-03 IN2015DN03229A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/058574 WO2014055073A1 (fr) 2012-10-03 2012-10-03 Antigènes associés à la maladie inflammatoire chronique de l'intestin

Publications (1)

Publication Number Publication Date
IN2015DN03229A true IN2015DN03229A (fr) 2015-10-02

Family

ID=50435280

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3229DEN2015 IN2015DN03229A (fr) 2012-10-03 2012-10-03

Country Status (22)

Country Link
US (2) US9695232B2 (fr)
EP (1) EP2903629B1 (fr)
JP (1) JP6158933B2 (fr)
KR (1) KR102011549B1 (fr)
CN (2) CN104768563B (fr)
AU (1) AU2012391490B2 (fr)
CA (1) CA2886152C (fr)
CO (1) CO7380754A2 (fr)
DK (1) DK2903629T3 (fr)
ES (1) ES2743423T3 (fr)
HK (1) HK1212220A1 (fr)
HU (1) HUE044927T2 (fr)
IL (1) IL237856B (fr)
IN (1) IN2015DN03229A (fr)
MX (1) MX364535B (fr)
PH (1) PH12015500662A1 (fr)
PL (1) PL2903629T3 (fr)
PT (1) PT2903629T (fr)
RU (1) RU2612878C2 (fr)
SG (1) SG11201502404WA (fr)
SI (1) SI2903629T1 (fr)
WO (1) WO2014055073A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222377B2 (en) 2007-10-30 2012-07-17 Philogen, S.P.A. Antigen associated with rheumatoid arthritis
WO2014055073A1 (fr) 2012-10-03 2014-04-10 Philogen S.P.A. Antigènes associés à la maladie inflammatoire chronique de l'intestin
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
CN110997718B (zh) * 2017-06-07 2023-11-10 菲洛根股份公司 血管内皮生长因子/抗纤连蛋白抗体融合蛋白
US10858412B2 (en) * 2019-03-06 2020-12-08 Deka Biosciences, Inc. Antibody variable domain regions fused to IL-10 variant molecules
WO2020249757A1 (fr) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugués comprenant un dianticorps à chaîne unique et de l'interleukine-15 ou l'interleukine-15 et un domaine sushi du récepteur alpha de l'interleukine-15
MX2023000948A (es) 2020-07-20 2023-04-14 Deka Biosciences Inc Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10).
US20230285585A1 (en) 2020-07-22 2023-09-14 Philogen S.P.A. Treatment of pulmonary hypertension
WO2023175077A1 (fr) 2022-03-17 2023-09-21 Philogen S.P.A Anticorps anti-ed-a pour traitement d'hypertension pulmonaire

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE425839C (de) 1923-08-09 1926-03-02 Optische Anstalt C P Goerz Akt Verfahren zur Erzeugung des Schleifdruckes und der Schleifrelativbewegung zwischen dem Gegenstande, dessen Oberflaeche durch Schleifen bearbeitet werden soll (Glas, Linse usw.), und der Schleifflaeche des umlaufenden Schleifwerkzeuges
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5420012A (en) 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1992017604A1 (fr) 1991-03-26 1992-10-15 Otsuka Pharmaceutical Factory, Inc. Anticorps monoclonal anti-eda
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DK0617706T3 (da) 1991-11-25 2001-11-12 Enzon Inc Multivalente antigenbindende proteiner
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
CA2351346C (fr) 1998-12-10 2015-09-01 Phylos, Inc. Echaffaudages de proteines pour des mimes d'anticorps et autres proteines de liaison
DE60121733T2 (de) 2000-02-24 2007-08-09 Philogen S.P.A. Zusamensetzungen und Verfahren zur Behandlung von Angiogenese in pathologischen Schädigungen
US20030152572A1 (en) 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
WO2001083816A2 (fr) 2000-05-04 2001-11-08 Philogen S.R.L. Procedes de detection de tumeurs
KR20030045056A (ko) 2000-09-07 2003-06-09 쉐링 악티엔게젤샤프트 ＥＤｂ-피브로넥틴 도메인의 수용체
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US20020187100A1 (en) 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
EP1224943A1 (fr) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin comme marqueur de tumeurs, détectée par des anticorps exprimés sur phages
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
WO2004000216A2 (fr) 2002-06-21 2003-12-31 Duke University Fragments d'anticorps anti-tenascine et minicorps pour le traitement du lymphome
JP4790413B2 (ja) 2002-10-08 2011-10-12 イミューノメディクス、インコーポレイテッド 抗体療法
WO2004054622A1 (fr) 2002-12-13 2004-07-01 Immunomedics, Inc. Immunoconjugues comprenant une liaison intracellulaire clivable
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
WO2004094612A2 (fr) 2003-04-22 2004-11-04 A & G Pharmaceutical, Inc. Anticorps monoclonaux specifiques de cancer
WO2005009366A2 (fr) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restauration d'une fonction vasculaire
WO2005086612A2 (fr) 2003-07-29 2005-09-22 Immunomedics, Inc. Conjugues glucidiques fluores
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
US20060024724A1 (en) 2004-07-30 2006-02-02 Robert Hussa Oncofetal fibronectin as a marker for health and disease
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
DE602005014665D1 (de) 2004-11-09 2009-07-09 Philogen Spa Antikörper gegen tenascin-c
AU2005317684B2 (en) 2004-12-23 2012-02-16 Molmed Spa Conjugation product
KR101281208B1 (ko) 2005-05-11 2013-07-26 필로겐 에스.피.에이. 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질
EP1893244A4 (fr) 2005-06-23 2009-06-24 Univ Emory Agents pour l'imagerie
TW201444869A (zh) * 2005-06-30 2014-12-01 Abbvie Inc Ｉｌ-１２／ｐ４０結合蛋白
CA2650953A1 (fr) 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combinaison d'un anticorps l19-sip anti domaine ed-b de la fibronectine et d'un anticorps anti-egfr
AU2007247380B2 (en) 2006-05-08 2011-03-10 Philogen Spa Antibody-targeted cytokines for therapy
ES2609813T3 (es) 2007-04-02 2017-04-24 Philogen S.P.A. Antígeno nuevo asociado con la neovasculatura de metástasis tumorales
EA017995B1 (ru) 2007-07-25 2013-04-30 Филоджен С.П.А. Антиген, связанный с вариантами рака легкого и лимфомами
US8222377B2 (en) 2007-10-30 2012-07-17 Philogen, S.P.A. Antigen associated with rheumatoid arthritis
CA2748401C (fr) * 2009-01-07 2017-09-12 Philogen S.P.A. Antigenes associes a l'endometriose
AU2009336800A1 (en) 2009-01-07 2011-07-21 Philogen S.P.A. Cancer treatment
ES2712997T3 (es) 2009-08-05 2019-05-17 Philogen Spa Selección como diana de neovasculatura de médula ósea
WO2012041451A1 (fr) 2010-09-29 2012-04-05 Philogen S.P.A. Liant à base de thiazolidine pour la conjugaison de médicaments à des anticorps
ES2706428T3 (es) 2011-07-27 2019-03-28 Philogen Spa Inmunoconjugado de IL-12
WO2014055073A1 (fr) 2012-10-03 2014-04-10 Philogen S.P.A. Antigènes associés à la maladie inflammatoire chronique de l'intestin
EP2988784A1 (fr) 2013-04-25 2016-03-02 Philogen S.p.A. Conjugués anticorps-médicament
JP2016519111A (ja) 2013-04-26 2016-06-30 フィロゲン エスピーエー 細胞外マトリックス成分に対する抗体にコンジュゲートしたｉｌ４
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
JP2016500670A (ja) 2016-01-14
EP2903629A4 (fr) 2016-07-27
PT2903629T (pt) 2019-09-10
CO7380754A2 (es) 2015-09-10
PH12015500662B1 (en) 2015-05-18
PH12015500662A1 (en) 2015-05-18
US20150361161A1 (en) 2015-12-17
US10239939B2 (en) 2019-03-26
IL237856B (en) 2019-11-28
CA2886152A1 (fr) 2014-04-10
MX2015003908A (es) 2015-08-05
MX364535B (es) 2019-04-29
CN104768563B (zh) 2020-02-28
PL2903629T3 (pl) 2019-12-31
DK2903629T3 (da) 2019-08-05
HUE044927T2 (hu) 2019-11-28
CN111329994A (zh) 2020-06-26
KR20150061648A (ko) 2015-06-04
ES2743423T3 (es) 2020-02-19
SI2903629T1 (sl) 2019-09-30
AU2012391490B2 (en) 2018-02-15
US9695232B2 (en) 2017-07-04
KR102011549B1 (ko) 2019-08-16
US20180044408A1 (en) 2018-02-15
AU2012391490A1 (en) 2015-04-30
WO2014055073A1 (fr) 2014-04-10
EP2903629A1 (fr) 2015-08-12
EP2903629B1 (fr) 2019-07-10
JP6158933B2 (ja) 2017-07-05
CN104768563A (zh) 2015-07-08
IL237856A0 (en) 2015-05-31
SG11201502404WA (en) 2015-05-28
HK1212220A1 (en) 2016-06-10
RU2612878C2 (ru) 2017-03-13
RU2015115399A (ru) 2016-11-27
CA2886152C (fr) 2020-01-14
NZ631476A (en) 2017-06-30

Similar Documents

Publication Publication Date Title
IN2015DN03229A (fr)
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
EA201400579A1 (ru) Антитела к il-36r
EA032986B1 (ru) Пирролобензодиазепины
MA41031A (fr) Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
EP2590671A4 (fr) Immunoglobulines à domaine variable double et leurs utilisations
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
WO2012047631A3 (fr) Compositions et procédés utiles dans le traitement et le diagnostic d'une maladie intestinale inflammatoire
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
MX2013005015A (es) Anticuerpos anti-il-23.
PH12014502406A1 (en) Anti-il-23p19 antibodies
MY163368A (en) Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
MX2013004979A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX341579B (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
EP2694530A4 (fr) Nouveaux peptides qui se lient à des types de cmh (complexe majeur d'histocompatibilité) de classe ii et leur utilisation en vue de diagnostic et de traitement
MX365403B (es) Peptidos y metodos para usarlos.
MX356163B (es) Anilinas sustituidas como antagonistas de ccr(4).
IN2014DN06662A (fr)
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
FR2979346B1 (fr) Nanocorps anti-vcam-1
CL2013001445A1 (es) Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer.
BR112014032733A2 (pt) aparelho e métodos para a coleta de fardos
MY178558A (en) Antigens associated with inflammatory bowel disease
IN2015DN02818A (fr)
WO2015092435A3 (fr) Conjugués pour le traitement de maladie inflammatoire et identification de patients susceptibles de bénéficier d'un tel traitement